Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 11.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 183,963 shares of the company’s stock after acquiring an additional 18,585 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. owned approximately 0.11% of Allogene Therapeutics worth $914,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Oppenheimer & Co. Inc. increased its stake in Allogene Therapeutics by 24.9% in the 1st quarter. Oppenheimer & Co. Inc. now owns 15,050 shares of the company’s stock valued at $137,000 after buying an additional 3,000 shares during the period. AlphaCrest Capital Management LLC boosted its holdings in shares of Allogene Therapeutics by 83.4% in the first quarter. AlphaCrest Capital Management LLC now owns 49,574 shares of the company’s stock valued at $452,000 after acquiring an additional 22,540 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of Allogene Therapeutics by 58.6% during the first quarter. MetLife Investment Management LLC now owns 36,326 shares of the company’s stock worth $331,000 after acquiring an additional 13,419 shares during the period. BlackRock Inc. raised its holdings in Allogene Therapeutics by 8.6% during the first quarter. BlackRock Inc. now owns 7,086,233 shares of the company’s stock worth $64,557,000 after purchasing an additional 560,279 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Allogene Therapeutics by 8.2% in the first quarter. Dimensional Fund Advisors LP now owns 805,987 shares of the company’s stock valued at $7,344,000 after purchasing an additional 61,259 shares during the period. Institutional investors and hedge funds own 78.51% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the company. HC Wainwright cut their target price on Allogene Therapeutics from $23.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Oppenheimer reaffirmed an “outperform” rating and set a $28.00 price target on shares of Allogene Therapeutics in a research note on Thursday, August 3rd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.35.
Allogene Therapeutics Stock Performance
Shares of NASDAQ:ALLO opened at $2.99 on Tuesday. Allogene Therapeutics, Inc. has a one year low of $2.31 and a one year high of $11.10. The business’s fifty day moving average price is $3.14 and its two-hundred day moving average price is $4.35. The stock has a market cap of $503.15 million, a PE ratio of -1.33 and a beta of 0.83.
Allogene Therapeutics Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
- Five stocks we like better than Allogene Therapeutics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- The most upgraded stocks in November have two things in common
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Monday.com rocked earnings like it’s the weekend
- Golden Cross Stocks: Pattern, Examples and Charts
- Plan to own one retailer? Make it this one
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.